The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the underwriters, in connection with the $173 million public offering by Terns Pharmaceuticals, Inc. of 14,064,048 SEC-registered shares of common stock and pre-funded warrants to purchase 2,380,952 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase additional shares. The shares are listed on the Nasdaq Global Select Market under the symbol “TERN.”

Headquartered in Foster City, California, Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity.

The Davis Polk corporate team included partner Yasin Keshvargar and associates Michael Schuster and Wenyi Xu. Partner David R. Bauer and associate Adrian Rabin provided intellectual property advice. Partner Mario J. Verdolini and associates Ted Lee and Carter Ballentine Allison provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post